S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response

Calithera Biosciences (CALA) Competitors

$0.02
0.00 (0.00%)
(As of 04/12/2024 ET)

CALA vs. ATHX, OBSV, RNAZ, PKBO, IGNY, BTTX, SMFL, SINT, SCPS, and STAB

Should you be buying Calithera Biosciences stock or one of its competitors? The main competitors of Calithera Biosciences include Athersys (ATHX), ObsEva (OBSV), TransCode Therapeutics (RNAZ), Peak Bio (PKBO), Ignyte Acquisition (IGNY), Better Therapeutics (BTTX), Smart for Life (SMFL), Sintx Technologies (SINT), Scopus BioPharma (SCPS), and Statera Biopharma (STAB). These companies are all part of the "medical" sector.

Calithera Biosciences vs.

Calithera Biosciences (NASDAQ:CALA) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk, community ranking and dividends.

Calithera Biosciences has a beta of -0.17, indicating that its share price is 117% less volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, indicating that its share price is 190% less volatile than the S&P 500.

Athersys received 24 more outperform votes than Calithera Biosciences when rated by MarketBeat users. Likewise, 60.83% of users gave Athersys an outperform vote while only 59.93% of users gave Calithera Biosciences an outperform vote.

CompanyUnderperformOutperform
Calithera BiosciencesOutperform Votes
341
59.93%
Underperform Votes
228
40.07%
AthersysOutperform Votes
365
60.83%
Underperform Votes
235
39.17%

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Athersys N/A N/A -223.03%

19.4% of Athersys shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by insiders. Comparatively, 0.0% of Athersys shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Athersys had 1 more articles in the media than Calithera Biosciences. MarketBeat recorded 2 mentions for Athersys and 1 mentions for Calithera Biosciences. Athersys' average media sentiment score of 0.24 beat Calithera Biosciences' score of 0.00 indicating that Athersys is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Calithera Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Athersys
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Calithera Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Athersys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Calithera Biosciences has higher revenue and earnings than Athersys.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera Biosciences$9.75M0.01-$39.65MN/AN/A
Athersys$146K2.03-$72.53M-$2.030.00

Summary

Athersys beats Calithera Biosciences on 6 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALA vs. The Competition

MetricCalithera BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$97,000.00$6.58B$4.88B$7.64B
Dividend YieldN/A3.04%2.95%3.92%
P/E RatioN/A17.26257.0319.38
Price / Sales0.01332.902,402.5395.00
Price / CashN/A31.6837.1331.69
Price / Book-0.055.164.614.29
Net Income-$39.65M$147.57M$103.90M$214.71M
7 Day PerformanceN/A-2.30%-2.32%-2.30%
1 Month PerformanceN/A-1.14%-0.36%-0.06%
1 Year PerformanceN/A4.79%14.39%8.81%

Calithera Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATHX
Athersys
0 of 5 stars
$0.01
flat
N/A-99.5%$352,000.00$146,000.000.0024Analyst Report
News Coverage
Gap Down
OBSV
ObsEva
0 of 5 stars
$0.01
flat
N/A-94.6%$390,000.00$20.11M-0.0148Analyst Report
News Coverage
Gap Down
RNAZ
TransCode Therapeutics
3.0967 of 5 stars
$0.64
-1.5%
$480.00
+74,876.6%
-99.8%$403,000.00N/A0.0019Short Interest ↓
Gap Down
PKBO
Peak Bio
0 of 5 stars
$0.01
flat
N/AN/A$118,000.00$610,000.000.0021News Coverage
High Trading Volume
IGNY
Ignyte Acquisition
0 of 5 stars
$0.01
flat
N/AN/A$38,000.00N/A0.00N/A
BTTX
Better Therapeutics
2.4728 of 5 stars
$0.01
flat
$6.00
+69,667.4%
-99.1%$429,000.00N/A-0.0154Positive News
Gap Down
SMFL
Smart for Life
0 of 5 stars
$0.67
-2.9%
N/A-99.1%$537,000.00$17.77M0.00145Short Interest ↑
Gap Down
High Trading Volume
SINT
Sintx Technologies
0 of 5 stars
$0.03
flat
N/A-98.6%$578,000.00$2.63M-0.0141Short Interest ↑
High Trading Volume
SCPS
Scopus BioPharma
0 of 5 stars
$0.00
flat
N/AN/A$34,000.00N/A0.0013
STAB
Statera Biopharma
0 of 5 stars
$0.00
flat
N/A-96.6%$33,000.00$1.49M0.0046News Coverage
Negative News

Related Companies and Tools

This page (NASDAQ:CALA) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners